Gilead Sciences, Inc.GILDNASDAQ
Loading
Operating cash flow minus capital expenditures
3Y CAGR
+4.3%/yr
vs +2.8%/yr prior
5Y CAGR
+4.7%/yr
Consistent
Acceleration
+1.5pp
Accelerating
Percentile
P57
Within normal range
vs 5Y Ago
1.3x
Solid growth
Streak
1 yr
Consecutive declineStable
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $9.46B | -8.2% |
| 2024 | $10.30B | +38.9% |
| 2023 | $7.42B | -11.1% |
| 2022 | $8.34B | -22.8% |
| 2021 | $10.80B | +43.7% |
| 2020 | $7.52B | -9.6% |
| 2019 | $8.32B | +11.3% |
| 2018 | $7.48B | -33.9% |
| 2017 | $11.31B | -30.6% |
| 2016 | $16.30B | - |